A+KIDS, a web-based antipsychotic registry for North Carolina youths: an alternative to prior authorization

Insights

The Antipsychotics-Keeping It Documented for Safety (A+KIDS) registry successfully enrolled thousands of children, improving antipsychotic safety monitoring. This initiative provides valuable clinical data beyond standard prescription claims.

Area of Science:

  • Pediatric pharmacology
  • Public health initiatives
  • Child and adolescent psychiatry

Background:

  • Rising antipsychotic use in U.S. children necessitates improved safety monitoring.
  • Current safety-monitoring guideline compliance is notably low.
  • The North Carolina Division of Medical Assistance created the A+KIDS registry to address these issues.

Purpose of the Study:

  • Establish a functional web-based safety registry for pediatric antipsychotic use.
  • Collect and analyze clinical data from the A+KIDS registry.
  • Evaluate the effectiveness of the A+KIDS registry in enhancing safety.

Main Methods:

  • Prescribers of antipsychotics for children aged 12 and under were surveyed starting April 2011.
  • Registry data was linked with North Carolina Medicaid prescription claims for comprehensive analysis.
  • Prescriber types and registration volumes were examined.

Main Results:

  • Within six months, 730 prescribers registered 5,532 patients, with 19% under age seven.
  • By month six, 72% of all antipsychotic fills were registered.
  • Top diagnoses included mood disorders, autism spectrum disorders, and disruptive behavior disorders, with aggression as the primary target symptom.

Conclusions:

  • The A+KIDS registry demonstrates rapid adoption and success in its initial phase.
  • The registry yields crucial clinical insights not obtainable from claims data alone.
  • Future work will focus on detailed antipsychotic utilization analysis and safety enhancements.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...